News
Apr 21, 2014
CardioCell Scientific Advisory Board Chair Joins “Novel Technologies in Stem Cell Research” Panel at the 2014 Stem Cell Summit
CAMBRIDGE, MASS. – STEM CELL SUMMIT 2014 – April 21, 2014 – CardioCell announces a presentation by noted cardiologist Dr. Stephen Epstein, the company’s Scientific Advisory Board chair, as well as director, translational and vascular biology research at MedStar Heart Institute and clinical professor of medicine at Georgetown University. In the talk, “Angiomyogenesis and Stem Cell Therapy: New Strategies to Surmount Obstacles to Success,” Dr. Epstein offers new therapy concepts leveraging data derived from CardioCell, whose novel method of growing stem cells under chronic hypoxic conditions is yielding promising clinical-trial results.
Details: |
Dr. Stephen Epstein’s talk covers “New Strategies to Surmount Obstacles to Success for Angiomyogenesis and Stem Cell Therapy.” He discusses:
|
When: |
Thurs., April 24, 2014, at 11:20 a.m. Eastern time |
Where: |
Stem Cell Summit 2014 – 3rd Stem Cell Commercialization & Partnering Conference |
Contact: |
Kimberly Stoddard, kimberly@townsendteam.com, (415) 806-5793 |
About CardioCell, LLC
Founded in San Diego, Calif., in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique, patented, ischemia-tolerant mesenchymal stem cells (itMSCs) manufactured under cGMP conditions. CardioCell is a subsidiary of Stemedica Cell Technologies Inc., a global biotechnology company that manufactures adult allogeneic stem cells. The company’s technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in the former Soviet Union, Europe and the United States. CardioCell therapies offer a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. The company has an exclusive, worldwide license from Stemedica to explore therapeutic indications for unmet cardiovascular needs, such as acute myocardial infarction (AMI), chronic heart failure (CHF) and peripheral artery disease (PAD). For more information, visit www.stemcardiocell.com.